

Lyndsey L Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2412198/publications.pdf>

Version: 2024-02-01

24
papers

700
citations

687363

13
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

642
citing authors

#	ARTICLE	IF	CITATIONS
1	Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. <i>Epilepsia</i> , 2019, 60, 2224-2234.	5.1	103
2	Screening of conventional anticonvulsants in a genetic mouse model of epilepsy. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 326-339.	3.7	89
3	Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. <i>Journal of Natural Products</i> , 2019, 82, 3047-3055.	3.0	77
4	Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq. <i>PLoS Genetics</i> , 2016, 12, e1006398.	3.5	76
5	Unexpected Efficacy of a Novel Sodium Channel Modulator in Dravet Syndrome. <i>Scientific Reports</i> , 2017, 7, 1682.	3.3	56
6	Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization. <i>AAPS Journal</i> , 2021, 23, 91.	4.4	38
7	Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations. <i>Scientific Reports</i> , 2021, 11, 14948.	3.3	32
8	Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. <i>British Journal of Pharmacology</i> , 2021, 178, 4826-4841.	5.4	32
9	Interactions between cannabidiol and Δ^9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome. <i>British Journal of Pharmacology</i> , 2020, 177, 4261-4274.	5.4	30
10	Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. <i>ACS Chemical Neuroscience</i> , 2021, 12, 330-339.	3.5	28
11	Citalopram and Cannabidiol. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 525-533.	1.4	24
12	Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic. <i>Journal of Biological Chemistry</i> , 2019, 294, 6157-6171.	3.4	20
13	Adolescent behavioral abnormalities in a <i>Scn1a</i> ^{+/-} mouse model of Dravet syndrome. <i>Epilepsy and Behavior</i> , 2020, 103, 106842.	1.7	16
14	Measuring Drug Metabolism Kinetics and Drug-Drug Interactions Using Self-Assembled Monolayers for Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry. <i>Analytical Chemistry</i> , 2016, 88, 8604-8609.	6.5	13
15	Evaluation of the Possible Anticonvulsant Effect of Δ^9 -Tetrahydrocannabinolic Acid in Murine Seizure Models. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 46-57.	2.9	13
16	The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome. <i>Neuropharmacology</i> , 2022, 205, 108897.	4.1	9
17	The Heat Sensing Trpv1 Receptor Is Not a Viable Anticonvulsant Drug Target in the <i>Scn1a</i> ^{+/-} Mouse Model of Dravet Syndrome. <i>Frontiers in Pharmacology</i> , 2021, 12, 675128.	3.5	8
18	A nutraceutical product, extracted from <i>Cannabis sativa</i> , modulates voltage-gated sodium channel function. <i>Journal of Cannabis Research</i> , 2022, 4, .	3.2	7

#	ARTICLE	IF	CITATIONS
19	<i>In Vitro</i> Screening of Three Commercial Cannabis-Based Products on ATP-Binding Cassette and Solute-Carrier Transporter Function. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 304-317.	2.9	6
20	Cannabichromene and Δ^9 -Tetrahydrocannabinolic Acid Identified as Lactate Dehydrogenase-A Inhibitors by <i>in Silico</i> and <i>In Vitro</i> Screening. <i>Journal of Natural Products</i> , 2021, 84, 1469-1477.	3.0	6
21	Olivetolic acid, a cannabinoid precursor in <i>Cannabis sativa</i> , but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. <i>Journal of Cannabis Research</i> , 2022, 4, 2.	3.2	6
22	A Potential Drug-Gene-Drug Interaction Between Cannabidiol, CYP2D6*4, and Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 422-424.	1.4	5
23	The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations. <i>Neuropharmacology</i> , 2021, 182, 108371.	4.1	3
24	In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. <i>European Journal of Pharmacology</i> , 2022, 922, 174836.	3.5	3